Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Immatics N.V.NASDAQ: IMTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of €59.19M rose 41.2% year over year, ahead of the +27.4% change in trailing-twelve-month research & development. Sequentially, it rose 19.2% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.
Context
- Research & development amounted to 380.9% of revenue in FY2025, up 285.8 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +41.2% holds above the trailing-twelve-month pace of +27.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 183.83M EUR
- Year-over-year change
- +24.1%
- 4-year CAGR
- +20.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 183.83M | +24.1% |
| FY2024 | 2024-12-31 | 148.08M | +24.8% |
| FY2023 | 2023-12-31 | 118.66M | +11.1% |
| FY2022 | 2022-12-31 | 106.78M | +21.9% |
| FY2021 | 2021-12-31 | 87.57M | — |
Research & Development vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +27.4% is the 2nd highest of 11, against a peer median of -7.4%.
- Research & development amounts to 539.2% of revenue for IMTX, versus a peer median of 118.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €2.18B EUR | -0.6% | +9.6% | 82.6% | |
| LTM Sep 2026 | $378.58M USD | -9.4% | +7.3% | 27.9% | |
| LTM Mar 2026 | $259.11M USD | +17.2% | +34.4% | 67.2% | |
| LTM Mar 2026 | €201.11M EUR | +27.4% | +19.9% | 539.2% | |
| LTM Mar 2026 | $151.83M USD | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $129.09M USD | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $127.65M USD | +60.8% | +33.1% | 590.6% | |
| LTM Mar 2026 | $106.27M USD | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $94.68M USD | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $53.36M USD | -10.8% | +5.5% | 118.4% | |
| LTM Mar 2026 | $10.18M USD | -92.4% | -48.4% | 44.0% | |
| Peer median (excluding IMTX) | — | -7.4% | +6.4% | 118.4% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.76M | 172.83M | 54M | 155.84M | 48.27M |
| Cost of Revenue | 87.57M | 106.78M | 118.66M | 0 | 0 |
| Gross Profit | (52.81M) | 66.05M | (64.67M) | 155.84M | 48.27M |
| Gross Margin | -151.9% | 38.2% | -119.8% | 100.0% | 100.0% |
| Research & Development | 87.57M | 106.78M | 118.66M | 148.08M | 183.83M |
| Selling, General & Admin | 33.81M | 36.12M | 38.2M | 46.45M | 51.18M |
| Operating Expenses | 121.05M | 142.88M | 155.72M | 194.45M | 230.28M |
| Depreciation & Amortization | 5.47M | 6.84M | 7.23M | 12.23M | 12.4M |
| EBITDA | (87.3M) | 50.04M | (88.93M) | 34.46M | (185.09M) |
| EBITDA Margin | -251.1% | 29.0% | -164.7% | 22.1% | -383.5% |
| Operating Income | (86.29M) | 29.95M | (101.73M) | (38.62M) | (182.02M) |
| Operating Margin | -248.2% | 17.3% | -188.4% | -24.8% | -377.1% |
| Interest Income | 133K | 2.48M | 13.85M | 25M | 17.18M |
| Interest Expense | 566K | 1.04M | 831K | 886K | 946K |
| Other Income / Expenses | (7.04M) | 12.08M | 4.73M | 59.96M | (16.42M) |
| Income Before Tax | (93.34M) | 42.04M | (96.99M) | 21.35M | (198.44M) |
| Pre-Tax Margin | -268.5% | 24.3% | -179.6% | 13.7% | -411.1% |
| Income Tax Expense | 0 | 4.55M | 0 | 6.13M | (1.99M) |
| Net Income | (95.06M) | 37.51M | (96.99M) | 15.22M | (196.45M) |
| Net Margin | -273.5% | 21.7% | -179.6% | 9.8% | -407.0% |
| EPS (Basic) | (1.51) | 0.55 | (1.20) | 0.14 | (1.54) |
| EPS (Diluted) | (1.51) | 0.54 | (1.20) | 0.14 | (1.54) |
| Weighted Avg Shares | 62.91M | 67.22M | 80.55M | 108.7M | 122.35M |
| Weighted Avg Shares (Diluted) | 62.91M | 68.82M | 80.55M | 106.8M | 122.35M |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.